Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Athanassios Argiris

Showing results (61-70 of 122) with videos related to

Pageof 13
Sort By:
Oral Oncology|June 27, 2012
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancerHoward S Moskowitz, William E Gooding, Sufi M Thomas, et al.
Head & Neck|May 13, 2014
Posttraumatic stress disorder symptoms in newly diagnosed patients with head and neck cancer and their partnersDonna M Posluszny, Angela Liegey Dougall, Jonas T Johnson, et al.
Cancer Research|April 3, 2015
CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor PrognosisHyun-Bae Jie, Patrick J Schuler, Steve C Lee, et al.
Head & Neck|June 24, 2014
Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neckMin Yao, Nicholas Galanopoulos, Pierre Lavertu, et al.
Cancer Biology & Therapy|June 9, 2006
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancerAthanassios Argiris, Ezra Cohen, Theodore Karrison, et al.
Investigational New Drugs|September 2, 2011
Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignanciesAthanassios Argiris, Trevor M Feinstein, Lin Wang, et al.
Annals of Surgical Oncology|November 8, 2017
Induced Bias Due to Crossover Within Randomized Controlled Trials in Surgical Oncology: A Meta-regression Analysis of Minimally Invasive versus Open Surgery for the Treatment of Gastrointestinal CancerGeorge Garas, Sheraz R Markar, George Malietzis, et al.
Cancer Epidemiology|March 25, 2016
Characterization of human papillomavirus antibodies in individuals with head and neck cancerKrystle A Lang Kuhs, Michael Pawlita, Sandra P Gibson, et al.
Oral Oncology|September 6, 2011
Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancerAthanassios Argiris, Steve C Lee, Trevor Feinstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapyAthanassios Argiris, Bruce E Brockstein, Daniel J Haraf, et al.
Pageof 13

Showing results (61-70 of 122) with videos related to

Sort By:
Pageof 13
Oral Oncology|June 27, 2012
Serum biomarker modulation following molecular targeting of epidermal growth factor and cyclooxygenase pathways: a pilot randomized trial in head and neck cancerHoward S Moskowitz, William E Gooding, Sufi M Thomas, et al.
Head & Neck|May 13, 2014
Posttraumatic stress disorder symptoms in newly diagnosed patients with head and neck cancer and their partnersDonna M Posluszny, Angela Liegey Dougall, Jonas T Johnson, et al.
Cancer Research|April 3, 2015
CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor PrognosisHyun-Bae Jie, Patrick J Schuler, Steve C Lee, et al.
Head & Neck|June 24, 2014
Phase II study of bevacizumab in combination with docetaxel and radiation in locally advanced squamous cell carcinoma of the head and neckMin Yao, Nicholas Galanopoulos, Pierre Lavertu, et al.
Cancer Biology & Therapy|June 9, 2006
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancerAthanassios Argiris, Ezra Cohen, Theodore Karrison, et al.
Investigational New Drugs|September 2, 2011
Phase I and pharmacokinetic study of dasatinib and cetuximab in patients with advanced solid malignanciesAthanassios Argiris, Trevor M Feinstein, Lin Wang, et al.
Annals of Surgical Oncology|November 8, 2017
Induced Bias Due to Crossover Within Randomized Controlled Trials in Surgical Oncology: A Meta-regression Analysis of Minimally Invasive versus Open Surgery for the Treatment of Gastrointestinal CancerGeorge Garas, Sheraz R Markar, George Malietzis, et al.
Cancer Epidemiology|March 25, 2016
Characterization of human papillomavirus antibodies in individuals with head and neck cancerKrystle A Lang Kuhs, Michael Pawlita, Sandra P Gibson, et al.
Oral Oncology|September 6, 2011
Serum biomarkers as potential predictors of antitumor activity of cetuximab-containing therapy for locally advanced head and neck cancerAthanassios Argiris, Steve C Lee, Trevor Feinstein, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2004
Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapyAthanassios Argiris, Bruce E Brockstein, Daniel J Haraf, et al.
Pageof 13